Patents by Inventor Thomas W. Dubensky

Thomas W. Dubensky has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for activating “stimulator of interferon gene”13 dependent signalling
    Patent number: 11040053
    Abstract: The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce human STING-dependent type I interferon production, wherein the cyclic purine dinucleotides present in the composition are 2?-fluoro substituted, bis-3?,5? CDNs, and most preferably one or more 2?,2?-diF-Rp,Rp, bis-3?,5?CDNs.
    Type: Grant
    Filed: October 21, 2019
    Date of Patent: June 22, 2021
    Assignee: CHINOOK THERAPEUTICS, INC.
    Inventors: George Edwin Katibah, David Kanne, Leonard Sung, Kelsey Gauthier, Laura Hix Glickman, Justin Leong, Sarah M. McWhirter, Thomas W. Dubensky, Jr.
  • Compositions and methods for activating “stimulator of interferon gene”-dependent signalling
    Patent number: 10906930
    Abstract: The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce human STING-dependent type I interferon production, wherein the cyclic purine dinucleotides present in the composition are 2?- or 3?-mono-fluoro substituted, or 2?3?-di-fluoro substituted mixed linkage 2?,5?-3?,5? CDNs.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: February 2, 2021
    Assignees: CHINOOK THERAPEUTICS, INC., NOVARTIS AG
    Inventors: George Edwin Katibah, David Kanne, Leonard Sung, Kelsey Gauthier, Laura Hix Glickman, Justin Leong, Sarah M. McWhirter, Thomas W. Dubensky, Jr., Jeffrey McKenna, Stephen M. Canham, Chudi Obioma Ndubaku
  • COMPOSITIONS AND METHODS FOR ACTIVATING "STIMULATOR OF INTERFERON GENE"-DEPENDENT SIGNALLING
    Publication number: 20200282049
    Abstract: The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce STING-dependent type I interferon production, wherein the cyclic purine dinuclotides present in the composition are substantially pure 2?,5?,2?,5? and 2?,5?,3?,5? CDNs, and prefereably Rp,Rp stereosiomers thereof.
    Type: Application
    Filed: May 18, 2020
    Publication date: September 10, 2020
    Applicants: ADURO BIOTECH, INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Thomas W. Dubensky, JR., David B. Kanne, Meredith Lai Ling Leong, Edward Emile Lemmens, Laura H. Glickman, Russell E. Vance
  • COMPOSITIONS AND METHODS FOR ACTIVATING "STIMULATOR OF INTERFERON GENE" - DEPENDENT SIGNALLING
    Publication number: 20200179431
    Abstract: The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce human STING-dependent type I interferon production, wherein the cyclic purine dinucleotides present in the composition are 2?-fluoro substituted, bis-3?,5? CDNs, and most preferably one or more 2?,2?-diF-Rp,Rp, bis-3?,5?CDNs.
    Type: Application
    Filed: October 21, 2019
    Publication date: June 11, 2020
    Applicant: ADURO BIOTECH, INC.
    Inventors: George Edwin Katibah, David Kanne, Leonard Sung, Kelsey Gauthier, Laura Hix Glickman, Justin Leong, Sarah M. McWhirter, Thomas W. Dubensky, JR.
  • Compositions and methods for activating “stimulator of interferon gene”-dependent signalling
    Patent number: 10653774
    Abstract: The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce STING-dependent type I interferon production, wherein the cyclic purine dinucleotides present in the composition are substantially pure 2?,5?,2?,5? and 2?,5?,3?,5? CDNs, and preferably Rp,Rp stereoisomers thereof.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: May 19, 2020
    Assignees: ADURO BIOTECH, INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Thomas W. Dubensky, Jr., David B. Kanne, Meredith Lai Ling Leong, Edward Emile Lemmens, Laura H. Glickman, Russell E. Vance
  • VACCINES FOR HSV-2
    Publication number: 20200023057
    Abstract: Compositions of recombinant HSV-2 proteins and an agonist of the innate immune system, such as an adjuvant, are provided as a vaccine. Proteins include an envelope glycoprotein and a structural protein other than an envelope glycoprotein, e.g., a capsid or tegument protein. The vaccine is for use in either HSV-2 seropositive or seronegative subjects.
    Type: Application
    Filed: July 16, 2019
    Publication date: January 23, 2020
    Inventors: Thomas W. Dubensky, JR., Nancy A. Hosken, Scott H. Robbins, Margaret D. Moore
  • Compositions and methods for activating “stimulator of interferon gene”—dependent signalling
    Patent number: 10449211
    Abstract: The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes), In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce human STING-dependent type I interferon production, wherein the cyclic purine dinucleotides present in the composition are 2?-fluoro substituted, bis-3?,5?CDNs, and most preferably one or more 2?,2?-diF-Rp,Rp, bis-3?,5?CDNs.
    Type: Grant
    Filed: March 9, 2016
    Date of Patent: October 22, 2019
    Assignee: ADURO BIOTECH, INC.
    Inventors: George Edwin Katibah, David Kanne, Leonard Sung, Kelsey Gauthier, Laura Hix Glickman, Justin Leong, Sarah M. McWhirter, Thomas W. Dubensky, Jr.
  • Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
    Patent number: 10414789
    Abstract: It is an object of the present invention to provide novel and highly active cyclic-di-nucleotide (CDN) immune stimulators that activates DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides that induce STING-dependent TBK1 activation, wherein the cyclic purine dinuclotides present in the composition are substantially pure Rp,Rp or Rp,Sp stereoisomers, and particularly substantially pure Rp,Rp, or RpSp CDN thiophosphate diastereomers.
    Type: Grant
    Filed: June 22, 2017
    Date of Patent: September 17, 2019
    Assignee: ADURO BIOTECH, INC.
    Inventors: Thomas W. Dubensky, Jr., David B. Kanne, Meredith Lai Ling Leong, Edward Emile Lemmens, Laura Hix Glickman
  • Vaccines for HSV-2
    Patent number: 10391164
    Abstract: Compositions of recombinant HSV-2 proteins and an agonist of the innate immune system, such as an adjuvant, are provided as a vaccine. Proteins include an envelope glycoprotein and a structural protein other than an envelope glycoprotein, e.g., a capsid or tegument protein. The vaccine is for use in either HSV-2 seropositive or seronegative subjects.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: August 27, 2019
    Assignee: IMMUNE DESIGN CORP.
    Inventors: Thomas W. Dubensky, Jr., Nancy A. Hosken, Scott H. Robbins, Margaret D. Moore
  • COMPOSITIONS AND METHODS FOR ACTIVATING "STIMULATOR OF INTERFERON GENE"-DEPENDENT SIGNALLING
    Publication number: 20190062365
    Abstract: The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce human STING-dependent type I interferon production, wherein the cyclic purine dinucleotides present in the composition are 2?- or 3?-mono-fluoro substituted, or 2?3?-di-fluoro substituted mixed linkage 2?,5?-3?,5? CDNs.
    Type: Application
    Filed: October 28, 2016
    Publication date: February 28, 2019
    Applicants: ADURO BIOTECH, INC., NOVARTIS AG
    Inventors: George Edwin KATIBAH, David KANNE, Leonard SUNG, Kelsey GAUTHIER, Laura Hix GLICKMAN, Justin LEONG, Sarah M. McWHIRTER, Thomas W. DUBENSKY, Jr., Jeffrey McKENNA, Stephen M. CANHAM, Chudi Obioma NDUBAKU
  • Compositions and methods for inhibiting “stimulator of interferon gene”-dependent signalling
    Patent number: 10189873
    Abstract: The invention provides compounds of the purine cyclic dinucleotide (CDN) class, useful as inhibitors of the STING (Stimulator of Interferon Genes) pathway, and methods of their administration to individuals in need thereof.
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: January 29, 2019
    Assignee: ADURO BIOTECH, INC.
    Inventors: Thomas W. Dubensky, Jr., David B. Kanne
  • METHODS AND COMPOSITIONS USING LISTERIA FOR ENHANCING IMMUNOGENICITY BY PRIME BOOST
    Publication number: 20190015488
    Abstract: Provided herein are prime-boost regimens and materials used therein. The prime-boost regimens enhance the immune response to a target antigen. The vaccines used for boost are comprised of recombinant attenuated metabolically active Listeria that encodes an expressible antigen that is cross-reactive with the target antigen. In some examples, the immune response is a cellular immune response.
    Type: Application
    Filed: January 29, 2018
    Publication date: January 17, 2019
    Applicant: ADURO BIOTECH, INC.
    Inventors: Thomas W. Dubensky, Jr., Dirk G. Brockstedt, Meredith Lai Ling Leong, Keith S. Bahjat
  • METHODS FOR IDENTIFYING INHIBITORS OF "STIMULATOR OF INTERFERON GENE"- DEPENDENT INTERFERON PRODUCTION
    Publication number: 20180369268
    Abstract: The present invention relates to the use cyclic-di-nucleotide and related scaffold molecules that measurably inhibit STING signaling, and methods for their use in identifying more potent inhibitors of STING signaling. In particular, the methods provided can be used to identify potent inhibitors of STING signaling, which are useful in the treatment of autoimmune and inflammatory diseases. Also provided are compounds having STING inhibitory activity useful in the treatment of autoimmune and inflammatory diseases.
    Type: Application
    Filed: December 16, 2016
    Publication date: December 27, 2018
    Applicant: ADURO BIOTECH, INC.
    Inventors: George Edwin KATIBAH, David KANNE, Leonard SUNG, Justin LEONG, Sarah M. McWHIRTER, Thomas W. DUBENSKY, JR.
  • ENGINEERED LISTERIA AND METHODS OF USE THEREOF
    Publication number: 20180280489
    Abstract: The invention provides a bacterium containing a polynucleotide comprising a nucleic acid encoding a heterologous antigen, as well as fusion protein partners. Also provided are vectors for mediating site-specific recombination and vectors comprising removable antibiotic resistance genes.
    Type: Application
    Filed: June 18, 2018
    Publication date: October 4, 2018
    Applicant: ADURO BIOTECH, INC.
    Inventors: Thomas W. Dubensky, JR., Justin Skoble, Peter M. Lauer, David N. Cook
  • COMPOSITIONS AND METHODS FOR ACTIVATING "STIMULATOR OF INTERFERON GENE" - DEPENDENT SIGNALLING
    Publication number: 20180064745
    Abstract: The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes), In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce human STING-dependent type I interferon production, wherein the cyclic purine dinucleotides present in the composition are 2?-fluoro substituted, bis-3?,5?CDNs, and most preferably one or more 2?,2?-diF-Rp,Rp, bis-3?,5?CDNs.
    Type: Application
    Filed: March 9, 2016
    Publication date: March 8, 2018
    Applicant: ADURO BIOTECH, INC.
    Inventors: George Edwin Katibah, David Kanne, Leonard Sung, Kelsey Gauthier, Laura Hix Glickman, Justin Leong, Sarah M. McWhirter, Thomas W. Dubensky, Jr.
  • Vaccines for HSV-2
    Patent number: 9895435
    Abstract: Compositions of recombinant HSV-2 proteins and an agonist of the innate immune system, such as an adjuvant, are provided as a vaccine. Proteins include an envelope glycoprotein and a structural protein other than an envelope glycoprotein, e.g., a capsid or tegument protein. The vaccine is for use in either HSV-2 seropositive or seronegative subjects.
    Type: Grant
    Filed: May 16, 2013
    Date of Patent: February 20, 2018
    Assignee: IMMUNE DESIGN CORP.
    Inventors: Thomas W. Dubensky, Jr., Nancy A. Hosken, Scott H. Robbins, Margaret D. Moore
  • USE OF STING AGONIST AS CANCER TREATMENT
    Publication number: 20180028553
    Abstract: Methods and compositions for treating cancer by intratumorally administering a stimulator of interferon genes (STING) agonist are disclosed herein.
    Type: Application
    Filed: October 13, 2017
    Publication date: February 1, 2018
    Inventors: Thomas F. Gajewski, Seng-ryong Woo, Leticia Corrales, Thomas W. Dubensky, Jr., David Kanne, Meredith Lai Ling Leong, Laura Hix Glickman, Edward Emile Lemmens
  • Methods and compositions using for enhancing immunogenicity by prime boost
    Patent number: 9878024
    Abstract: Provided herein are prime-boost regimens and materials used therein. The prime-boost regimens enhance the immune response to a target antigen. The vaccines used for boost are comprised of recombinant attenuated metabolically active Listeria that encodes an expressible antigen that is cross-reactive with the target antigen. In some examples, the immune response is a cellular immune response.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: January 30, 2018
    Assignee: ADURO BIOTECH, INC.
    Inventors: Thomas W. Dubensky, Jr., Dirk G. Brockstedt, Meredith Lai Ling Leong, Keith S. Bahjat
  • ENGINEERED LISTERIA AND METHODS OF USE THEREOF
    Publication number: 20180000917
    Abstract: The invention provides a bacterium containing a polynucleotide comprising a nucleic acid encoding a heterologous antigen, as well as fusion protein partners. Also provided are vectors for mediating site-specific recombination and vectors comprising removable antibiotic resistance genes.
    Type: Application
    Filed: September 18, 2017
    Publication date: January 4, 2018
    Applicant: ADURO BIOTECH, INC.
    Inventors: Thomas W. Dubensky, Jr., Justin Skoble, Peter M. Lauer, David N. Cook
  • COMPOSITIONS AND METHODS FOR ACTIVATING "STIMULATOR OF INTERFERON GENE"-DEPENDENT SIGNALLING
    Publication number: 20170333552
    Abstract: The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce STING-dependent type I interferon production, wherein the cyclic purine dinucleotides present in the composition are substantially pure 2?,5?,2?,5? and 2?,5?,3?,5? CDNs, and preferably Rp,Rp stereoisomers thereof.
    Type: Application
    Filed: July 31, 2017
    Publication date: November 23, 2017
    Applicants: ADURO BIOTECH, INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Thomas W. Dubensky, JR., David B. Kanne, Meredith Lai Ling Leong, Edward Emile Lemmens, Laura H. Glickman, Russell E. Vance